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Ending Eclampsia seeks to expand access to proven, 
underutilized interventions and commodities for the 
prevention, early detection, and treatment of pre-
eclampsia and eclampsia (PE/E) and strengthen 
global partnerships 
Ending Eclampsia is working in Nigeria and Bangladesh to assess the 
level of program activities, gaps and challenges around prevention and 
treatment of PE/E and magnesium sulfate (MgSO4). The project will 
build upon this landscape analysis to expand services to detect and 
manage PE/E, develop and support implementation of strategic plans 
for replicating the intervention package, and increase global PE/E 
evidence shared through knowledge and learning platforms. 
 
Ending Eclampsia’s legacy will be: 
 A dramatically enlarged and robust body of evidence—synthesized, 
translated, and shared through global knowledge and learning 
networks—that informs strategies to scale up underutilized yet 
effective PE/E interventions in low resource settings. 
 Greatly expanded implementation of underutilized interventions, 
commodities and approaches in targeted countries to substantially 
increase access to services for the prevention and treatment of 
PE/E as the result of improved programming that addresses the 
ability to apply and to monitor the scale up of high impact 
practices. 
 The adoption of improved PE/E programming in countries where 
Ending Eclampsia did and did not undertake work, as the result of 
its global thought leadership and coordination 
 Strengthened capacity of local institutions to support scale up of 
defined PE/E interventions. 
Ending Eclampsia will contribute to the goal of reducing maternal 
morbidity and mortality caused by PE/E with the objective to increase 
appropriate prevention and treatment of severe PE/E in USAID priority 
countries. 
FACTS ABOUT PE/E 
 Each day, about 800 women die 
from preventable causes related 
to pregnancy and childbirth 
 The second most frequent direct 
cause of maternal mortality is a 
result of pregnancy-induced high 
blood pressure leading to PE/E 
 Babies born prematurely, due to 
their mothers experiencing PE/E, 
are also at higher risk of dying 
 Women in developing countries 
are 300 times more likely to die 
from eclampsia than women in 
developed countries 
 The World Health Organization 
recommends magnesium sulfate 
as the safest, most effective, and 
lowest-cost treatment for severe 
pre-eclampsia and eclampsia 
 The need for magnesium sulfate 
is greatest in low-income 
countries of sub-Saharan Africa 
and South Asia, where pregnancy 
and childbirth are less safe and 
65%-85% of the population is 
rural, with limited access to life-
saving health care 
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PROJECT DEVELOPMENT HYPOTHESIS 
Ending Eclampsia has a clear project development 
hypothesis. It is assumed that if the capacity of frontline 
primary health care (PHC) providers is improved, for 
detecting and managing PE/E particularly during the ANC 
period, key policy barriers will be removed: a loading dose 
of MgSO4 is provided at the PHC level, use of aspirin 
prescribed to pregnant women who are at risk of 
developing PE/E, appropriate use of antihypertensive 
medication for pregnant women with raised blood 
pressure, then there will be early diagnosis of PE/E; and 
use of low-cost underutilized effective intervention for the 
management of PE/E, which will ultimately reduce the 
morbidity and mortality of mothers and newborns. Our 
development hypothesis relies on the assumption that if 
the quality of care at the PHC level for pregnant women 
can be improved, use of MgSO4 for the management of 
PE/E is ensured and the knowledge and skills are 
included in the PHC service providers’ curriculum there 
will be sustainable improvement in the provision of 
maternal and newborn health. 
 
 
LEVELS OF PROGRAM 
IMPLEMENTATION 
Interventions will be implemented at four levels: 
 Community level 
 Primary Health Care (PHC) level 
 Referral level facilities  
 Policy level 
In addition, there are various categories of providers such 
as physicians, paramedics, nurse/midwives and 
fieldworkers that would be involved in providing the 
loading dose depending on the Ministry of Health (MoH) 
approval. The project activities will be implemented in 
partnership with national obstetrics and gynecology 
(Ob/Gyn) and midwifery societies in each country. 
IMPLEMENTATION COUNTRIES 
The interventions will initially be implemented in 
Bangladesh and Nigeria and, subsequently, the 
learning from these two countries will be validated 
and scaled up or replicated in Ethiopia and Pakistan 
in Year Two of the project. The evidence generated 
from each country will be fed into the global evidence 
repository for disseminating through knowledge and 
learning networks to facilitate use of high-quality 
underutilized interventions and commodities and to 
reduce maternal mortality and morbidity around the 
globe particularly in USAID priority countries.  
 
LANDSCAPE ANALYSIS  
From PE/E perspective, we describe landscaping analysis 
as a form of analysis to understand the overall policies, 
programs and service environment around PE/E in a 
particular geographical area be it nation, state or local 
district level. The primary goals and objectives of the 
landscape analysis are to identify the policy and 
program level activities; gaps and challenges around 
prevention and treatment of PE/E, using loading dose of 
MgSO4 at the PHC level, aspirin prophylaxis and use of 
antihypertensive in pregnancy at the national level in 
each country.  
We will also review the extent to which non-government 
organizations, development partners and others 
(including professional associations) are involved in 
PE/E activities, the policy makers, stakeholders’ and 
service providers understanding of PE/E and use of 
loading dose of MgSO4 in the management of PE/E. The 
PE/E patients’ perspective will also be gathered to feed 
into the landscaping analysis. 
SCALING UP 
The project will promote and support effective use of 
evidence that can be used to support 
institutionalization and scale-up of identified best 
practices. Scaling up is defined here as  
“efforts to increase the impact of 
innovations successfully tested in 
pilot or experimental projects so as 
to benefit more people and to foster 
policy and programme development 
on a lasting basis” 
—EXPANDNET/WHO, 2008 
Ending Eclampsia project will share lessons with MOH 
staff and partners working in PE/E in each target 
country and use the ExpandNet/WHO scale up 
framework to ensure a coordinated approach to scaling 
up and to understand lessons and evidence on best 
practices. Regional workshops will be conducted using 
the ExpandNet ‘nine steps for scaling up a strategy’ as a 
guide to encourage a context specific strategy that is 
flexible to respond to innovations from individual 
countries. One of the nine steps focuses on Monitoring 
and Evaluation; Ending Eclampsia will document scale 
up activities through a country case study approach and 
use of the WHO quality of care indicators. 
 
IMPACT 
Findings from Ending Eclampsia will change the global 
conversation on maternal mortality, putting a greater 
focus on this preventable cause of death and will be 
used to improve access to life-saving care for the 
approximately 3 million women at risk of pre-eclampsia 
and eclampsia every year. 
 
 
Please address any inquiries about the Ending Eclampsia project to 
Charlotte E. Warren, the project director: cwarren@popcouncil.org. 
 
www.popcouncil.org/research/ending-eclampsia1 
